Your Health, We Care
Release date: 2025-04-18 10:32:52 Recommended: 263
Focusing on the clinical value of finerenone, the medical community is conducting in-depth discussions.
The drug reduces the rate of protein excretion by selectively inhibiting mineralocorticoid receptors.
Data from the phase III clinical trial showed an average reduction of 31% in urine protein levels and a 29% slowdown in the decline of kidney function.
It is mainly for patients with type 2 diabetes who have chronic metabolic problems. The inclusion criteria of the study showed that the glomerular filtration rate of the subjects should be in the range of 25-75ml/min/1.73m² with microproteinuria.
The daily cost of medication is about $4.2, and the annual cost of treatment is about $1,500. It is important to note that actual expenditures may fluctuate depending on dose adjustments or adjuvant therapy.
Treatment decisions need to be made in conjunction with individualized medical needs.
Compared with spironolactone, the incidence of electrolyte abnormalities was reduced by 40%. Compared with eplerenone, it lowers blood pressure by 15%, but serum potassium levels need to be monitored regularly.
Dietary intervention delayed medication requirements in 24% of patients. 150 minutes of moderate-intensity exercise per week combined with a low-sodium diet improved urine protein by 18% in some cases.
Electrolytes are measured every two weeks at the beginning of treatment and monthly when they are stable. For special populations, it is recommended to start with half a dose and gradually adjust to the target dose.
Medical decisions should be based on a comprehensive assessment, with regular testing and dynamic adjustments constituting key elements of treatment success. Personalized solutions under the guidance of a professional team can maximize the desired treatment goals.
